- Key facts & figures
- Sanofi share
- Analysts / Vara Consensus
- Reports & publications
- Results & presentations
- Corporate governance
Annual General Meetings
- Our publications
- Being a shareholder
- Becoming a shareholder
- Shareholders committee
- US investors
- Regulated information in France
Investor Relations Awards
- Get to know Sanofi
- Working at Sanofi
- Our Expertise, your future
- Join Sanofi
- Being our partner
- Understanding science discovering
- Developing and marketing innovative solutions
- Manufacturing and supply
- Healthcare Solutions
- Our approach
- Improving access to healthcare
- Working together
- Acting ethically
- Preserving the environment
- ‘LE HUB’ eMAG
We concentrate our research efforts where the most pressing medical needs and public health issues are, bringing solutions to patients and contributing to a healthier society worldwide.
With 382 million people currently living with diabetes worldwide, this disease constitutes a major public health challenge. Sanofi's aim is to offer all-round therapeutic solutions to patients – medicines, medical devices, services, etc. Among other areas, our research concerns the development of drugs with sustained action or supplied in a combination, and a range of different pathological conditions induced by diabetes such as nephropathy, neuropathy, retinopathy, etc.
In the field of prevention, Sanofi Pasteur is exploring novel technologies and the most recent scientific findings in order to develop safe and effective vaccines with a single or combined target against complex diseases that affect populations throughout the world, such as dengue fever and infections caused by C. difficile. At the same time, our research efforts are focusing on the treatment of multi-resistant hospital-acquired infections and malaria thanks to new antibiotics, antivirals, anti-infective agents and agents that stimulate resistance to infections.
With Sanofi Genzyme, we are committed to developing breakthrough therapies for patients who might otherwise have few treatment options.
Our research efforts are focusing mainly on rare diseases, such as Gaucher disease, Pompe disease, Fabry disease and Niemann-Pick disease.
Our work in the immunology and inflammation fields is centred on discovering and developing innovative healthcare solutions to immune mediated diseases such as rheumatoid arthritis, lupus erythematosus and psoriasis, as well as chronic inflammatory disease such as asthma and atopic dermatitis - to name a few.
Over the past 30 years, medical advances have contributed to a significant decline of mortality from cardiovascular diseases. However, cardiovascular diseases still account for the largest number of deaths worldwide, with over 17 million annual deaths, representing 30% of all global death. By 2030, the number of people who die from cardiovascular diseases, mainly from heart disease and strokes, is expected to reach 23.3 million (source: World Health Organization). Among others, our efforts are on the correction of metabolic disorders – including hypercholesterolemia – and their cardiovascular consequences.
Sanofi has a strong heritage in oncology research, and notably in chemotherapy. Its aim is to combat cancer in all its different forms by carrying out research on the different pathways involved in the development, growth and propagation of cancer cells. The oncology R&D portfolio contains a range of innovative therapeutic agents with different mechanisms of action. Through collaborations focusing on novel therapeutic approaches including immuno-oncology, we reinforced our presence in this area.
We are committed to becoming a long term partner to the Multiple Sclerosis community by working to deliver scientific advancements that will have a significant impact on the lives of people living with MS.
Alzheimer’s and Parkinson’s diseases are the two most frequent neurodegenerative diseases. They affect approximately 27 million people worldwide, heavily impacting patients’ and caregivers’ lives and gradually lead to a loss of autonomy. The medical needs are still major, in particular, due to the absence of treatments preventing or slowing down the disease.
The ambition of our Research is to contribute to fighting these disabling diseases, in particular by preventing or delaying the disease progression, and to deliver innovative and high medical value solutions to patients.
Our research also includes programs in ophthalmology in particular to address unmet medical needs in pathologies such as uveitis and other rare eye conditions.
Sanofi, via its animal health company Merial, discovers and develops products to enhance the health, well-being and performance of a wide range of animals.
- Group sites
- Legal Notice
- Cookies policy
- Cookies settings
- Corporate Code of Ethics